(5-amino-3-triazolo[1,5-a]quinazolinyl)-(4-morpholinyl)methanone

(5-Amino-3-triazolo[1,5-a]quinazolinyl)-(4-morpholinyl)methanone, also known as **AZD3885**, is a potent and selective **inhibitor of the enzyme Aurora A kinase**.

Here's why it's important for research:

**1. Aurora A kinase as a drug target:** Aurora A kinase is a key enzyme involved in cell division, particularly in the regulation of mitotic spindle assembly and chromosome segregation. It's a promising target for the development of anti-cancer drugs.

**2. Potential for cancer treatment:** AZD3885, by inhibiting Aurora A kinase, can potentially:
* Block tumor cell growth and proliferation
* Induce apoptosis (programmed cell death) in cancer cells
* Sensitize cancer cells to other chemotherapies

**3. Research and development:** AZD3885 has been extensively studied in preclinical models and has shown promising anti-tumor activity in various cancers, including leukemia, breast cancer, and lung cancer. It is currently in clinical trials to evaluate its safety and efficacy in human patients.

**4. Insights into Aurora A kinase function:** The study of AZD3885 and its interaction with Aurora A kinase provides valuable information about the enzyme's role in cell division and its potential as a therapeutic target.

**5. Potential for other applications:** Aurora A kinase is also implicated in other diseases, such as inflammation and autoimmune disorders. Therefore, inhibitors like AZD3885 might have potential applications beyond cancer treatment.

**Overall, (5-Amino-3-triazolo[1,5-a]quinazolinyl)-(4-morpholinyl)methanone (AZD3885) is a significant compound in cancer research, with the potential to contribute to the development of new and effective therapies for a variety of malignancies.**